Skip Navigation LinksHome > July 1, 2005 - Volume 39 - Issue 3 > Survival After Cancer Diagnosis in Persons With AIDS
JAIDS Journal of Acquired Immune Deficiency Syndromes:
Clinical Science

Survival After Cancer Diagnosis in Persons With AIDS

Biggar, Robert J MD*; Engels, Eric A MD*; Ly, Sonny MS†; Kahn, Amy MS‡; Schymura, Maria J PhD‡; Sackoff, Judith PhD†; Virgo, Phillip BS§; Pfeiffer, Ruth M PhD∥

Free Access
Article Outline
Collapse Box

Author Information

From the *Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD; †Epidemiology Program, New York City Department of Health and Mental Hygiene, New York, NY; ‡New York State Cancer Registry, New York State Department of Health, Albany, NY; §Computer Sciences Corporation, Rockville, MD; and ∥Biostatistics Branch, DCEG, NCI, NIH, DHHS, Bethesda, MD.

Received for publication November 24, 2004; accepted March 16, 2005.

The authors present this as their original work not under consideration elsewhere and have no conflict of interest with any aspect of this study.

Reprints: Robert J. Biggar, Viral Epidemiology Branch, DCEG, NCI, NIH, DHHS, 6120 Executive Boulevard, Room 8014, Bethesda, MD, 20852 (E-mail: biggarb@mail.nih.gov).

Collapse Box

Abstract

The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies. Similarly, the prognosis of cancer has also improved. To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000. Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis). Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence. The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types. By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer. For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types. In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers. We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS. Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.

The need to evaluate the impact of comorbid conditions on cancer prognosis has been recently emphasized.1 AIDS represents a special case, in which better medical management, particularly the use of advanced antiretroviral therapies (ARTs) to control HIV infection, has greatly improved prognosis since the mid-1990s. Highly effective ART prevents HIV replication and, with viral control, levels of immunity often improve or stabilize.2 In New York (NY) City, 24% of persons with AIDS (PWA) diagnosed between 1996 and 1998 died within 24 months of AIDS diagnosis compared with 57% of those diagnosed between 1990 and 1995.3 Cancer remains a common problem in PWA, however, and continues to have a bad prognosis.3 As the prevalence of HIV-infected persons increases in NY City4 and elsewhere,5,6 many of these HIV-infected persons develop cancer, whether of AIDS-related types or occurring incidentally. With the recent advances in HIV management, cancer patients with HIV only or AIDS can be treated more aggressively, which should result in a better prognosis with respect to the malignancy as well as AIDS. We linked cancer and HIV/AIDS Registry data in NY City to compare overall survival after cancer diagnosis in PWA and persons without AIDS from the general population. By analyzing only those with AIDS and not those with HIV only, we were assured that the subjects were immunosuppressed. We further grouped data according to the changing availability of ARTs over time. The malignancies analyzed were AIDS-related cancers, including Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and invasive cervical cancer, and a selection of non-AIDS-related cancers that occurred frequently enough to provide stable estimates of changing trends in periods with different types of ART. We present findings on the changing postcancer survival of PWA and on the disparity in the risk of dying with cancer between PWA and patients without AIDS, adjusted for demographic variables, over the course of the AIDS epidemic in NY City.

Back to Top | Article Outline

SUBJECTS

In May 2003, we linked data about persons from the statewide NY State Cancer Registry (754,615 registered cases) to persons registered in the NY City HIV/AIDS Registry to obtain information about the AIDS status of the cancer cases. A computer-based probabilistic linkage algorithm used personal data contained within the registries, including social security number; first, middle, and last names; birth date; sex; race; residence; and death date. Potential linkages were reviewed for accuracy by registry representatives legally authorized to see the data. After matching, all personal identifiers were deleted from the analysis data set. These previously described procedures have been shown to give highly reliable linkages and to provide analysis data containing no confidential information about subjects.7,8 Institutional review boards at the NY State Health Department, the NY City Department of Health and Mental Hygiene, and the National Cancer Institute (Bethesda, MD) approved the study.

We analyzed cancer records for NY City adults who were aged 15 through 69 years old at AIDS diagnosis and who were diagnosed with invasive cancer from 1980 through 2000. During these years, the NY State Cancer Registry considered cancer data for NY City to be complete. AIDS reporting started in 1981 and has been required by law since 1984. Cancers were classified using the recently introduced International Classification of Diseases for Oncology, third edition (ICD-O-3) codes9 for site (topography) and morphology, but we also provide NHL grade descriptors based on the Working Formulation using codes from ICD-O-210 to facilitate comparisons with previous classification systems. Cancers considered to be AIDS associated included KS (ICD-O-3 morphology code 9140), NHL (ICD-O-3 morphology codes 9590-9596 and 9670-9729), and cervical cancer (ICD-O-3 site codes 53.0-53.9).11 When we found persons with AIDS-defining cancers before AIDS onset, we set back the time of AIDS onset to the onset date of the AIDS-defining cancer. Central nervous system (CNS) lymphomas included any NHL types in the CNS (ICD-O-3 site codes 70.0-72.9), regardless of the morphology, because this information was often not provided. CNS NHLs were analyzed separately from non-CNS NHLs. Non-CNS NHL types were further divided into the types previously designated high grade and considered to be AIDS NHLs11 (immunoblastic lymphoma [ICD-O-3 morphology code 9684], Burkitt lymphoma [ICD-O-3 morphology code 9687], lymphoblastic lymphoma [ICD-O-3 morphology codes 9727-9729], and large-cell diffuse lymphoma [ICD-O-3 morphology code 9680]), other specified types, and nonspecified NHL types (ICD-O-3 morphology codes 9590-9599). The other specified NHLs were those with low or intermediate grade NHL in ICD-O-2,10 excluding large-cell diffuse NHL. Because only 7 lymphoblastic lymphomas (high grade) were diagnosed in PWA, they were included in all NHLs but not analyzed separately.

Non-AIDS-related cancers were classified by site except for Hodgkin lymphoma. At each site, tumors with morphology codes indicating KS or NHL were excluded. We also excluded all tumors with nonspecific morphologies (ICD-O-3 morphology codes 8000-8004) because we could not be sure that they were not KS or NHL. For statistical robustness, we limited analysis to first primary cancers with at least 50 specific diagnoses in PWA as well as testicular cancer. The analyzed non-AIDS-related malignancies included Hodgkin lymphoma (ICD-O-3 morphology codes 9650-9667) and cancers of the colorectum (ICD-O-3 site codes 18.0-20.9), anus (ICD-O-3 site codes 21.0-21.8), larynx (ICD-O-3 site codes 32.0-32.9), lung (ICD-O-3 site codes 34.0-34.9), female breast (ICD-O-3 site codes 50.0-50.9), prostate (ICD-O-3 site code 61.9), and testis (ICD-O-3 site codes 62.0-62.9). We acknowledge that some of these (eg, Hodgkin lymphoma and cancer of the anus) occur excessively in PWA,8 but they are not defined as AIDS-related cancers. We had no information about whether the PWA actually used ART at any time and only incomplete information about cancer therapies.

Back to Top | Article Outline

STATISTICAL METHODS

The primary outcome was 24-month overall survival from cancer diagnosis, with data censored at 24 months from cancer diagnosis or death, whichever occurred earlier. Death information was obtained only from the NY State Cancer Registry to avoid bias from having additional information on PWA. When deaths were recorded only in the HIV/AIDS Registry, subjects were censored as alive with cancer. Cancers in PWA that started before the AIDS diagnosis were considered to be in persons without AIDS until AIDS onset and thereafter in PWA. For descriptive purposes, unadjusted survival rates were estimated by life table analysis. AIDS diagnoses were grouped into 3 periods with respect to the availability of ARTs: 1980 through 1989 (when ARTs were unavailable or used to a limited degree), 1990 through 1995 (when effective single-drug and 2-drug regimens became widely used), and 1996 through 2000 (when highly effective ARTs, including protease inhibitors, were available).

To compare the risk of dying in PWA and persons without AIDS, we used Cox proportional hazard models (SAS version 8.2; SAS Institute, Cary, NC) that adjusted for age, sex, and race. Race was categorized as white versus nonwhite, with Hispanics included in the white category because the NY State Cancer Registry did not have data about Hispanic origin until the 1990s. To accommodate improvements in cancer therapy over time, we included the decade of cancer diagnosis in the model. AIDS was considered a time-dependent covariate. Survival time before AIDS diagnosis was included with the non-AIDS subjects, and time after AIDS was added to the appropriate cancer survival period. Further adjustments for variables such as HIV exposure group resulted in unstable models and were not included. We did not have adequate data to assess the impact of CD4 counts. Time-trend probability analyses (Ptrend) refer to changes in the adjusted death hazard ratios in the 3 calendar-year periods.

Back to Top | Article Outline

RESULTS

As of May 2003, 126,297 persons were registered with AIDS in the NY City HIV/AIDS Registry through December 31, 2000. Of these, we excluded 5761 persons who were not from NY City and 6659 persons because information essential to our study was missing from their records. The final analysis set had 113,877 PWA. In the 1980s, 50% were men who have sex with men (MSM, including MSM with additional risk factors), whereas in 1996 through 2000, only 21% were in this group. Correspondingly, the demographics of PWA changed considerably over the period of this study. The demographic profile of the PWA shifted by race (white or Hispanic: 64%, 56%, and 49% in 1980-1989, 1990-1995, and 1996-2000, respectively) and sex (male: 84%, 75%, and 67%, respectively) as the AIDS epidemic shifted from being primarily among MSM to being more common in intravenous drug users and heterosexuals. As of May 2003, 754,615 persons in NY City had been diagnosed with cancer.

In this database, 13,194 persons were found to have both cancer and AIDS. We excluded 2949 of these cancer cases from our analysis because the morphology was not sufficiently defined or because there were too few cases to analyze. In addition, 221 non-AIDS-related cancers and 80 AIDS-related cancers (41 NHLs and 39 cervix cancers) occurred in persons who were diagnosed with cancer more than 2 years (often, many years) before the AIDS diagnosis. Therefore, their follow-up time with cancer was during a time without AIDS. The final analysis included 9015 AIDS-related cancers and 929 non-AIDS-related cancers of 8 types in PWA. Table 1 (AIDS cancers) and Table 2 (non-AIDS-related cancers) present 24-month overall survival rates estimated by actuarial methods and adjusted 24-month death hazard ratios for specific cancer by time period and, for comparison, the survival time for persons without AIDS in 1996 through 2000.

Table 1
Table 1
Image Tools
Table 2
Table 2
Image Tools
Back to Top | Article Outline
AIDS-Related Cancers

The NY State Cancer Registry recorded 7698 KS cases in NY City, of which 5927 (77%) were linked to AIDS cases. Of PWA with KS before 1996, 30% survived 24 months. Many KS cases occurred early in the AIDS epidemic, when mortality rates for PWA were high because ARTs were not available and supportive care was still being developed. In 1996 through 2000, when both were available, the 24-month survival rate was 58%. Among persons not known to have AIDS, 70% of those with KS remained alive. Most of these would have been PWA not reported to the NY City HIV/AIDS Registry (see Discussion section), and estimates of hazard ratios were therefore inappropriate.

Of 15,363 NHLs, including CNS NHLs, in the NY State Cancer Registry data for NY City, 3057 (20%) occurred in PWA. Survival to 24 months for PWA with non-CNS NHLs was less than 20% in early years but was 43% in 1996 through 2000 (see Table 1). Specifically, in 1996 through 2000, 24-month survival in PWA was 38% for large cell diffuse lymphoma, 44% for immunoblastic lymphoma, 48% for Burkitt lymphoma, and 50% for other specified NHLs (generally low-grade types). Of PWA with nonspecified NHL types, 37% survived to 24 months. Of persons without AIDS who had non-CNS NHL in 1996 through 2000, 65% survived 24 months; the best survival rate was for persons with other specified types (79% survived at least 24 months), whereas the worst prognosis was for adults with Burkitt NHL (31%). After adjusting for demographic changes, the adjusted 24-month death hazard ratios improved over time (P < 0.0001) for all non-CNS NHLs but remained higher in PWA than in persons without AIDS (1.9, 95% confidence interval [CI]: 1.6-2.2) in 1996 through 2000. By subtype, the death hazard ratios for non-CNS NHLs in 1996 through 2000 were 0.9 (95% CI: 0.5-1.8) for immunoblastic lymphoma, 0.6 (95% CI: 0.4-1.0) for Burkitt lymphoma, 1.7 (95% CI: 1.3-2.1) for large cell diffuse lymphoma, and 2.9 (95% CI: 1.9-4.6) for other specified NHLs. For nonspecified NHLs, a group that probably included many high-grade NHLs in PWA, the death hazard ratio in 1996 through 2000 was 1.7 (95% CI: 1.3-2.1).

Before 1996, few PWA with CNS NHL survived 24 months (see Table 1). In 1996 through 2000, however, 29% of PWA with CNS NHL survived 24 months compared with 39% of persons without AIDS who had CNS NHL. After adjustment for demographic and time changes, the 24-month death hazard ratio for CNS NHL in 1996 through 2000 was not significantly elevated in PWA (1.2, 95% CI: 0.9-1.6; see Table 1).

Only 2% of 8829 women with invasive cervical cancers had AIDS. Of PWA with cervical cancer, 64% survived 24 months in 1996 through 2000 compared with 79% of women without AIDS (see Table 1). In 1996 through 2000, the adjusted hazard ratio of dying within 24 months was 1.8 (95% CI: 1.1-3.2) for PWA compared with women without AIDS. The trend was not statistically significant.

Back to Top | Article Outline
Non-AIDS-Related Cancers

Two (5%) of 38 PWA with lung cancer in the 1980s survived 24 months, whereas 10% of 97 such persons survived 24 months in 1996 through 2000 (see Table 2). By comparison, 31% of lung cancer patients without AIDS survived 24 months. In PWA, the adjusted death hazard ratio in 1996 through 2000 (2.5, 95% CI: 2.0-3.1) showed no significant reduction from earlier hazard ratios. With large numbers of lung cancers available in this study, we were able to examine survival for squamous cell carcinoma and adenocarcinoma of the lung but still found no major improvements in any type (data not shown). For laryngeal cancer, survival and adjusted death hazard ratios seemed to worsen in PWA, but the trend was not significant.

For cancers of the colorectum, survival to 24 months increased to 63% of 28 cases in PWA during 1996 through 2000 compared with 73% in persons without AIDS (see Table 2). The adjusted death hazard ratios in PWA declined significantly over time. Although the adjusted hazard ratio in PWA remained elevated in 1996 through 2000, this increase was no longer statistically significant (1.6, 95% CI: 0.9-2.8). For PWA with anal cancer in 1996 through 2000, survival to 24 months was 76% in 23 cases (see Table 2) compared with 78% in persons without AIDS. The death hazard odds ratios (ORs) improved from 4.6 and 2.4 in the 1980s and early 1990s, respectively, to 0.9 (95% CI: 0.4-2.3) in 1996 through 2000 (Ptrend = 0.003).

For Hodgkin lymphoma, 19% of 49 PWA survived 24 months in 1980 through 1989 compared with 55% of 47 PWA in 1996 through 2000 (see Table 2). In persons without AIDS in 1996 through 2000, however, 89% survived 24 months. The hazard ratios for dying within 24 months showed considerable improvement in 1996 through 2000 (2.6; 95% CI: 1.6-4.1), although the overall trend was not significant (see Table 2).

In the 1980s, only 1 case of breast cancer was diagnosed in women with AIDS. With more women developing AIDS, breast cancer became more common. During 1996 through 2000, there were 28 cases in women with AIDS; 87% of these women survived 24 months (see Table 2) compared with 91% of women without AIDS. The adjusted hazard ratios for dying within 24 months declined significantly over time, being 1.6 (95% CI: 0.7-3.8) in 1996 through 2000. In men with AIDS during 1996 through 2000, the 24-month survival rate with prostate cancer (67%) remained considerably worse than in men without AIDS (95%). Although the adjusted hazard ratio for prostate cancer declined, the changes were not statistically significant. In 1996 through 2000, the 24-month death hazard ratio was 2.0 (95% CI: 1.0-4.3). Of 58 PWA who ever had testis cancer, 25 had it long before developing AIDS. Of 33 who had AIDS with testis cancer, few died within 24 months. Survival estimates were thus unstable. Death hazard ratios were also unstable, although they seemed to improve somewhat (see Table 2). In 1996 through 2000, the adjusted 24-month death hazard in PWA was 3.2 (95% CI: 0.4-23.8).

Back to Top | Article Outline

DISCUSSION

In PWA with AIDS-related and non-AIDS-related cancers, overall survival improved throughout the AIDS epidemic, especially in 1996 through 2000 relative to earlier years. Nonetheless, even in 1996 through 2000, for many cancers there remained increases in the risk of dying within 24 months in PWA compared with persons without AIDS who had the same cancers. These survival gaps can focus attention on opportunities to improve cancer care in PWA.

The prognosis depended on the cancer type in persons with and without AIDS. Although improvements in survival with NHL and Hodgkin lymphoma are apparent, there remains a considerable discrepancy between PWA and those without AIDS. Although PWA were more likely to have poor-prognosis (high-grade) NHL subtypes than persons without AIDS, we also found relatively poorer survival for PWA with low-grade subtypes. Survival has improved in recent years, however, indicating considerable progress in narrowing the survival gap. In this finding, our analysis agrees with an earlier report from NY City3 and with preliminary data about survival in San Francisco PWA with AIDS-related cancers.12 In non-CNS NHL, for example, the San Francisco investigators reported an overall survival of 26 months (median) in PWA diagnosed during the era of highly active ARTs compared with 7 months in an earlier period.6

In our study, we also found improvements in the survival of PWA with most types of non-AIDS-related cancers. With adjustments, some of the improvements were attenuated, but for most cancers, the 24-month death hazard was much lower in 1996 through 2000 than in earlier years. In our conclusions, we are more optimistic than some investigators. Lung cancer is the most frequent non-AIDS-related cancer in PWA and has been the focus of other published studies.12-16 These studies reported little or no change in survival despite improving ARTs, suggesting that the tumors may be diagnosed late or be more aggressive in PWA and that PWA with cancer may receive less intensive therapy. We also did not find survival for lung cancer to be improving significantly. The high mortality of lung cancer dominated the prognosis, however, and made it hard to observe any changes in survival occurring with better ARTs. We found considerable improvements in survival when cancer prognosis did not dominate survival. In this, we agree with the findings of a preliminary report describing better survival in San Francisco PWA with anal cancer in recent years12 and with a recent case-control study reporting similar survival in germ-cell cancers in persons with and without AIDS in the era of effective ARTs.17

Our analysis focuses on cancer survival in persons with and without AIDS. Because our linkage was between the AIDS and cancer registries, we could not identify HIV-infected persons who never developed AIDS, and they were included with the non-AIDS group. For the non-AIDS-related cancers, the impact on our results is minimal. In persons who developed AIDS, we used the time-dependent analysis to include their survival time with AIDS and cancer in the AIDS group. Some HIV-infected subjects with non-AIDS-related cancers would have died before progressing to an AIDS diagnosis and had their entire survival time assigned to the non-AIDS group. The prevalence of HIV/AIDS in NY City adults is estimated to be 1.3% to 1.8%, including undiagnosed and unreported persons.4 Therefore, the number of HIV-only subjects would be too small to have a large impact on the overwhelming proportion of cancer patients who are uninfected with HIV.

For AIDS-defining cancers (eg, NHL, KS, cervical cancer), the impact of misclassification depends on the proportion of cancers attributable to HIV/AIDS. In persons who were diagnosed as having AIDS, all survival time with the AIDS-defining cancer was assigned to the AIDS group, by definition. Twenty-three percent of the KS cases occurred among persons never reported to have AIDS, however. Because non-AIDS-related KS is rare, most of these KS cases were probably in persons with unreported AIDS, making a comparison between the AIDS and non-AIDS groups inappropriate. There are also unusual NHL subtypes that occur more commonly in PWA than others, such as CNS NHL or Burkitt NHL in adults. Some of these cases may have occurred in HIV-infected persons who were never reported as having AIDS. With such misclassification, our hazard ratios for these NHL types would be attenuated.

Socioeconomic factors bear on receiving care for AIDS and cancer. The demographic changes in NY City AIDS cases have been described in more detail elsewhere.3,4 Briefly, in the early AIDS epidemic, white MSM were particularly affected. This group generally had good access to health care services, but effective AIDS therapies were not available in the 1980s. In the 1990s, HIV infection became much more common in intravenous drug users and minorities. Although HIV/AIDS care greatly improved, particularly in the late 1990s, these groups probably used health care services less effectively than white MSM. When we incorporated HIV exposure route data into our analysis, the numbers in each group became small and models did not converge, but we believe that race provides an adequate surrogate for effective use of medical services. Even after adjusting for race as well as sex, age, and calendar-time of cancer onset, we continued to find improving death hazard ratios.

We used the new ICD-O-3 classification system9 to type our malignancies. In ICD-O-3 coding, NHL classification changed considerably and many NHL types coded in ICD-O-2 as specific types were reclassified as nonspecific because the distinctions in the old codes were not meaningful. The net effect is that nearly half of the NHL diagnoses in PWA and persons without AIDS (42.3% and 41.3%, respectively) were classified as nonspecific in ICD-O-3. Although the proportion of nonspecific tumors was similar, the mix of NHLs reclassified likely differed in PWA and persons without AIDS. The relatively poor survival of PWA with nonspecific NHLs suggests that many had subtypes previously considered to be high grade in ICD-O-2.10

We could not determine the relative contributions to the survival improvement attributable to a number of factors. We did not have cause-specific mortality, but AIDS certainly contributed to the mortality of those with AIDS and cancer. The definition of AIDS has been expanded to include less life-threatening conditions. Since 1993, it has included HIV-infected persons who are immunosuppressed but not ill.11 Earlier diagnoses should improve AIDS survival times regardless of therapy. Additionally, the improving therapy for PWA has been a major contributor to the improving survival of PWA with cancer. Screening for cancer and management of cancers in PWA have also improved over time. For statistical reasons, we limited adjustments for calendar-time of cancer onset to decades, but there have been some further advances in cancer care within decades. Finally, our estimates for survival could have been optimistic because of losses to follow-up in which deaths were not known. In this study, however, death information was considered to be more than 95% complete by the NY State Cancer Registry, and our follow-up was limited to 24 months after cancer onset to ensure high-quality survival data. Furthermore, in our study, the PWA with cancer had sufficient information to link them in both registries, and data of this quality would have permitted good matching to registry sources of death information. We therefore expect that losses of follow-up had little impact on our findings. Nevertheless, because our study was limited to 24 months, we cannot be sure that the improvements in survival have been sustained.

In this population-based study, we observed better survival of PWA with cancer during 1996 through 2000 when effective ARTs became available. A gap in overall survival remains between PWA and cancer and persons with cancer only, however. We hope that this report, showing that much has been accomplished, encourages the inclusion of HIV-infected persons and PWA in prevention programs, such as those directed at smoking cessation and Papanicolaou screening. Clinicians should be diligent about screening for, diagnosing, and treating cancer in PWA. When cancer is found, oncologists still face difficult choices in balancing risks and benefits of using potentially immunosuppressive treatments, requiring clinical decisions to be individualized.18,19 For cancers with a good prognosis, however, there is the prospect of prolonged survival even if the patient also has AIDS. When ARTs are effective in maintaining reasonable levels of immunity, optimal cancer treatments can be used. For PWA with cancers with a poor prognosis, decision making is more difficult, but aggressive approaches can be still considered.

Back to Top | Article Outline

ACKNOWLEDGMENTS

Drs. Robert Yarchoan and Richard Little, National Cancer Institute, Bethesda, MD, reviewed this paper to provide a helpful clinical perspective. The administrative support provided by Norma Kim and Emily Moser, Research Triangle Institute, Rockville, MD, and assistance with data management provided by Tim McNeel, Operations Management Systems, Rockville, MD, are greatly appreciated.

Back to Top | Article Outline

REFERENCES

1. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-2447.

2. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251-2257.

3. Fordyce EJ, Singh TP, Nash D, et al. Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr. 2002;30:111-118.

4. Centers for Disease Control and Prevention. Implementation of named HIV reporting-New York City, 2001. MMWR Morb Mortal Wkly Rep. 2004;52:1248-1250.

5. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among persons with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.

6. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV. Lancet. 1998;352:1725-1730.

7. Borges HT, Watkins J, Stafford R, et al. Linkage of selected AIDS and cancer registries in the United States. Journal of Registry Management. 2001;28:89-92.

8. Frisch M, Biggar RJ, Engels EA, et al. AIDS-related Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-1745.

9. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.

10. Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology. 2nd ed. Geneva: World Health Organization; 1990.

11. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-20.

12. Hessol NA, Scheer S. Increased cancer survival time for some, but not all cancers among adults with AIDS, in the era of HAART [abstract]. Presented at: Eighth International Conference on Malignancies in AIDS and Other Immunodeficiencies; 2004; Bethesda.

13. Sridhar KS, Flores MR, Raub WA, Jr, et al. Lung cancer in patients with human immunodeficiency virus infection compared to historic control subjects. Chest. 1992;102:1704-1708.

14. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer. 1996;15:325-339.

15. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer. 2000;88:563-569.

16. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer. 2003;89:457-459.

17. Powles T, Bower M, Shamash J, et al. Outcome of patients with HIV-related germ cell tumours: a case-control study. Br J Cancer. 2004;90:1526-1530.

18. Reier A, Lee F-C, Mitsuyasu RT. Attenuation of chemotherapy side effects in AIDS-associated malignancies. In: Feigal EG, Levine AM, Biggar RJ, eds. AIDS-Related Cancers and Their Treatment. New York: Marcel Dekker; 2000;255-280.

19. Little RF, Yarchoan R. Considerations in the management of HIV therapy in patients undergoing antineoplastic chemotherapy. In: Feigal EG, Levine AM, Biggar RJ, eds. AIDS-Related Cancers and Their Treatment. New York: Marcel Dekker; 2000;281-330.

Cited By:

This article has been cited 38 time(s).

Enfermedades Infecciosas Y Microbiologia Clinica
Non-AIDS defining malignancies or the sleeping giant: an update
Ortega, MEV
Enfermedades Infecciosas Y Microbiologia Clinica, 31(5): 319-327.
10.1016/j.eimc.2012.03.015
CrossRef
British Journal of Cancer
Prognosis in HIV-infected patients with non-small cell lung cancer
Sigel, K; Crothers, K; Dubrow, R; Krauskopf, K; Jao, J; Sigel, C; Moskowitz, A; Wisnivesky, J
British Journal of Cancer, 109(7): 1974-1980.
10.1038/bjc.2013.545
CrossRef
Scandinavian Journal of Infectious Diseases
HIV-associated lung cancer: Survival in an unselected cohort
Hoffmann, C; Kohrs, F; Sabranski, M; Wolf, E; Jaeger, H; Wyen, C; Siehl, J; Baumgarten, A; Hensel, M; Jessen, A; Schaaf, B; Vogel, M; Bogner, J; Horst, HA; Stephan, C
Scandinavian Journal of Infectious Diseases, 45(): 766-772.
10.3109/00365548.2013.810813
CrossRef
Dermatologic Clinics
HIV-associated Kaposi's sarcoma
Jessop, S
Dermatologic Clinics, 24(4): 509-+.
10.1016/j.det.2006.06.006
CrossRef
Blood
Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma
Little, RF; Aleman, K; Kumar, P; Wyvill, KM; Pluda, JM; Read-Connole, E; Wang, V; Pittaluga, S; Catanzaro, AT; Steinberg, SM; Yarchoan, R
Blood, 110(): 4165-4171.
10.1182/blood-2007-06-097568
CrossRef
Revue De Pneumologie Clinique
Lung cancer in HIV-positive patients
Lavole, A; Epaud, C; Rosencher, L; Gounant, V; Wislez, M; Cadranel, J
Revue De Pneumologie Clinique, 63(3): 167-175.

Journal of Clinical Oncology
Elevated incidence of lung cancer among HIV-infected individuals
Engels, EA; Brock, MV; Chen, JB; Hooker, CM; Gillison, M; Moore, RD
Journal of Clinical Oncology, 24(9): 1383-1388.
10.1200/JCO.2005.03.4413
CrossRef
Critical Reviews in Oncology Hematology
Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice
Mounier, N; Katlama, C; Costagliola, D; Chichmanian, RM; Spano, JP
Critical Reviews in Oncology Hematology, 72(1): 10-20.
10.1016/j.critrevonc.2008.10.013
CrossRef
Puerto Rico Health Sciences Journal
AIDS-Related Malignancies: Revisited
Caceres, W; Cruz-Amy, M; Diaz-Melendez, V
Puerto Rico Health Sciences Journal, 29(1): 70-75.

Bju International
Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study
Pantanowitz, L; Bohac, G; Cooley, TP; Aboulafia, D; Dezube, BJ
Bju International, 101(): 1519-1523.
10.1111/j.1464-410X.2008.07474.x
CrossRef
AIDS
Marked increase on the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
Piketty, C; Selinger-Leneman, H; Grabar, S; Duvivier, C; Bonmarchand, M; Abramowitz, L; Costagliola, D; Mary-Krause, M
AIDS, 22(): 1203-1211.

Cancer
Reversible features of cervical cancer in human immunodeficiency virus infection - Impaired access, impaired surveillance, impaired immunity, impaired outcomes
Little, RF; Denicoff, AM; Trimble, EL
Cancer, 112(): 2627-2630.
10.1002/cncr23499
CrossRef
Urology
Preliminary Results of Radiation Therapy for Prostate Cancer in Human Immunodeficiency Virus-Positive Patients
Ng, T; Stein, NF; Kaminetsky, J; Berman, S; Marans, HY; McDermott, B; Berson, AM
Urology, 72(5): 1135-1138.
10.1016/j.urology.2008.01.022
CrossRef
Cancer Epidemiology
The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era
Serraino, D; De Paoli, A; Zucchetto, A; Pennazza, S; Bruzzone, S; Spina, M; De Paoli, P; Rezza, G; Dal Maso, L; Suligoi, B
Cancer Epidemiology, 34(3): 257-261.
10.1016/j.canep.2010.03.011
CrossRef
Leukemia & Lymphoma
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment
Rubenstein, J; Ferreri, AJM; Pittaluga, S
Leukemia & Lymphoma, 49(): 43-51.
10.1080/10428190802311441
CrossRef
AIDS Education and Prevention
Review: the Need for Smoking Cessation Among Hiv-Positive Smokers
Nahvi, S; Cooperman, NA
AIDS Education and Prevention, 21(3): 14-27.

International Journal of Std & AIDS
Laryngeal cancer in acquired immunodeficiency syndrome
Shushan, S; Cinamon, U; Levy, D; Sokolov, M; Roth, Y
International Journal of Std & AIDS, 20(8): 582-584.
10.1258/ijsa.2008.008345
CrossRef
International Journal of Std & AIDS
Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006)
Mosam, A; Carrara, H; Shaik, F; Uldrick, T; Berkman, A; Aboobaker, J; Coovadia, HM
International Journal of Std & AIDS, 20(8): 553-556.
10.1258/ijsa.2008.008372
CrossRef
Thorax
Lung cancer in HIV infected patients: facts, questions and challenges
Cadranel, J; Garfield, D; Lavole, A; Wislez, M; Milleron, B; Mayaud, C
Thorax, 61(): 1000-1008.
10.1136/thx.2005.052373
CrossRef
American Journal of Epidemiology
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS
Hessol, NA; Pipkin, S; Schwarcz, S; Cress, RD; Bacchetti, P; Scheer, S
American Journal of Epidemiology, 165(): 1143-1153.
10.1093/aje/kwm017
CrossRef
Antiviral Therapy
Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study
Duval, X; Baron, G; Garelik, D; Villes, V; Dupre, T; Leport, C; Lert, F; Peretti-Watel, P; Ravoud, P; Spire, B
Antiviral Therapy, 13(3): 389-397.

Journal of Palliative Medicine
Prognosis in HIV-Associated Malignancies #214
Oppenheim, S
Journal of Palliative Medicine, 12(9): 835-836.
10.1089/jpm.2009.9578
CrossRef
Hiv Medicine
Laryngeal squamous cell carcinoma in HIV-positive patients: lack of association with human papillomavirus infection
Moyano, S; Ordi, J; Caballero, M; Garcia, F; Diaz, A; de Sanjose, S; Cardesa, A; Alos, L
Hiv Medicine, 10(): 634-639.
10.1111/j.1468-1293.2009.00737.x
CrossRef
Journal of the National Cancer Institute
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion
Lodi, S; Guiguet, M; Costagliola, D; Fisher, M; de Luca, A; Porter, K
Journal of the National Cancer Institute, 102(): 784-792.
10.1093/jnci/djq134
CrossRef
Journal of Clinical Oncology
AIDS-related malignancies: State of the art and therapeutic challenges
Spano, JP; Costagliola, D; Katlama, C; Mounier, N; Oksenhendler, E; Khayat, D
Journal of Clinical Oncology, 26(): 4834-4842.
10.1200/JCO.2008.16.8252
CrossRef
Medecine Et Maladies Infectieuses
Cancer and HIV: Understand and act
Amiel, C
Medecine Et Maladies Infectieuses, 38(): 625-641.
10.1016/j.medmal.2008.10.002
CrossRef
Chest
Epidemic of Lung Cancer in Patients With HIV Infection
Winston, TA; Man, SFP; Hull, M; Montaner, JS; Sin, DD
Chest, 143(2): 305-314.
10.1378/chest.12-1699
CrossRef
Clinics in Chest Medicine
Human Immunodeficiency Virus-Associated Lung Malignancies
Lambert, AA; Merlo, CA; Kirk, GD
Clinics in Chest Medicine, 34(2): 255-+.
10.1016/j.ccm.2013.01.008
CrossRef
European Journal of Cancer
CD4 lymphopenia to identify end-of-life metastatic cancer patients
Peron, J; Cropet, C; Tredan, O; Bachelot, T; Ray-Coquard, I; Clapisson, G; Chabaud, S; Philip, I; Borg, C; Cassier, P; Galy, IL; Sebban, C; Perol, D; Biron, P; Caux, C; Menetrier-Caux, C; Blay, JY
European Journal of Cancer, 49(5): 1080-1089.
10.1016/j.ejca.2012.11.003
CrossRef
AIDS
Elevated risk of lung cancer among people with AIDS
Chaturvedi, AK; Pfeiffer, RM; Chang, L; Goedert, JJ; Biggar, RJ; Engels, EA
AIDS, 21(2): 207-213.
10.1097/QAD.0b013e3280118fca
PDF (136) | CrossRef
AIDS
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
Polesel, J; Clifford, GM; Rickenbach, M; Dal Maso, L; Battegay, M; Bouchardy, C; Furrer, H; Hasse, B; Levi, F; Probst-Hensch, NM; Schmid, P; Franceschi, S; the Swiss HIV Cohort Study,
AIDS, 22(2): 301-306.
10.1097/QAD.0b013e3282f2705d
PDF (127) | CrossRef
AIDS
The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy
Grubb, JR; Moorman, AC; Baker, RK; Masur, H; the HOPS investigators,
AIDS, 20(8): 1095-1107.
10.1097/01.aids.0000226949.64600.f9
PDF (3334) | CrossRef
AIDS
Non-0002030-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities
Engels, EA
AIDS, 23(8): 875-885.
10.1097/QAD.0b013e328329216a
PDF (228) | CrossRef
AIDS
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy
The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group,
AIDS, 23(15): 2029-2037.
10.1097/QAD.0b013e32832e531c
PDF (384) | CrossRef
Current Opinion in Oncology
Update in HIV lymphoma
Noy, A
Current Opinion in Oncology, 18(5): 449-455.
10.1097/01.cco.0000239883.23839.ac
PDF (108) | CrossRef
Current Opinion in Oncology
The growing problem of non-AIDS-defining malignancies in HIV
Pantanowitz, L; Schlecht, HP; Dezube, BJ
Current Opinion in Oncology, 18(5): 469-478.
10.1097/01.cco.0000239886.13537.ed
PDF (152) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care
Brock, MV; Hooker, CM; Engels, EA; Moore, RD; Gillison, ML; Alberg, AJ; Keruly, JC; Yang, SC; Heitmiller, RF; Baylin, SB; Herman, JG; Brahmer, JR
JAIDS Journal of Acquired Immune Deficiency Syndromes, 43(1): 47-55.
10.1097/01.qai.0000232260.95288.93
PDF (417) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Survival After AIDS Diagnosis in Italy, 1999-2006: A Population-Based Study
Serraino, D; Zucchetto, A; Suligoi, B; Bruzzone, S; Camoni, L; Boros, S; Paoli, AD; Maso, LD; Franceschi, S; Rezza, G
JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(1): 99-105.
10.1097/QAI.0b013e3181a4f663
PDF (345) | CrossRef
Back to Top | Article Outline
Keywords:

HIV; prognosis; mortality; United States; highly active antiretroviral therapy

© 2005 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.